335 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 28597 | Laurence Buisseret | Breast | Institut Jules Bordet | ROSALINE | Trial closed for recruitment | Neoadjuvant study of targeting ROS1 in combination with endocrine therapy in invAsive Lobular carcINoma of the breast | laurence.buisseret@hubruxelles.be | 2 | 2 | ||
| 22746 | At least 2 but no more than 5 previous systemic regimens - For patients whose most recent systemic anti-DLBCL therapy induced a PR or CR, at least 60 days must have elapsed since the end of that therapy | Marie Maerevoet | Non-Hodgkin lymphoma | Karyopharm | SADAL | Trial closed for recruitment | SADAL - A Phase 2b Open-label study of Selinexor (KPT-330) in Patients with Relapsed/ Refractory Diffuse Large B-Cell Lymphoma (DLBCL) |
marie.maerevoet@hubruxelles.be | 2 | 2 | |
| 29756 | Mariana Brandao | Lung | AstraZeneca | SAFFRON | Trial open for recruitment | A phase III, randomised, Open-Label study of Savolitinib in combination with Osimertinib versus platinium-based doublet chemotherapy in participants with EGFR mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who have progressed on treatment with Osimertinib | mariana.brandao@hubruxelles.be | 3 | 3 | ||
| 29660 | Philippe Aftimos | Breast | IBCSG | SASCIA | Trial closed for recruitment | Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2 - negative breast cancer patients with high relapse risk after standard neoadjuvant treatment | philippe.aftimos@hubruxelles.be | 3 | 3 | ||
| 22936 | * Confirmed diagnosis of multiple myeloma according to the Salmon and Durie criteria * Has received at least three lines of treatment, exposed and refractory (or non-eligible) to the 5 major drugs (lenalidomide, pomalidomid, bortezomib, carfilzomib, dara |
Patrick Flamen | Myeloma | Bordet | SCARLET | Trial open for recruitment | Somatostatin receptors imaging in relapsing and refractory multiple myeloma patients (SCARLET) | patrick.flamen@hubruxelles.be | 2 | 2 | |
| 22770 | Eligible to receive R-GDP - with at least one but no more than two lines therapies - no previous treatment with Selinexor | Marie Maerevoet | Non-Hodgkin lymphoma | Lysarc | SELINDA | Trial closed | A Phase IB study of oral selinexor in adult patients with relapsed/refractory B-cell lymphoma receiving R-DHAOx or R-GDP | marie.maerevoet@hubruxelles.be | 2 | 2 | |
| 22848 | Smoker of quit smoking within the last 6 months, any tumors | Solid tumors | Institut Jules Bordet | Sevrage Tabagique | Trial open for recruitment | Impact of an emotion and craving regulation intervention on smoking cessation and maintenance among oncology patients : a randomized study | |||||
| 29698 | Nuria Kotecki | Multiple | Seagen | SGNPDL1V-001 | Trial open for recruitment | A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors | Nuria.Kotecki@hubruxelles.be | 1 | 1 | ||
| 29408 | Michail Ignatiadis | Breast | Seagen | SGNTUC-028 - HER2CLIMB-05 | Trial closed for recruitment | A randomized, double-blind, phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic HER2+ breast cancer (HER2CLIMB-05) | michail.ignatiadis@hubruxelles.be | 3 | 3 | ||
| 29767 | Saude Conde Rita | Rectum | Bordet | SHAPERS | Trial open for recruitment | Efficacy and safety of short-course radiotherapy (SCRT) versus total neoadjuvant therapy in older patients with locally advanced rectal cancer: a multicentre, open-label, randomised pragmatic clinical trial | 3 | 3 | |||
| 22641 | Biopsy mandatory, neoadjuvant | Alain Hendlisz | Colon | Celyad | SHRINK | Trial closed for recruitment | CELYAD SHRINK : An open-label, Phase I study to assess the safety and clinical activity of multiple doses of NKR-2, administered concurrently with the neoadjuvant Folfox treatment in patients with potentially resectable liver metastases from colorectal cancer | alain.hendlisz@hubruxelles.be | 1 | 1 | |
| 28658 | Joseph Kerger | Endometrium | Karyopharm | SIENDO/ENGOT-EN5 | Trial closed | A randomized phase III trial of maintenance with Selinexor / placebo after combination chemotherapy for patients with advanced or recurrent endometrial cancer | joseph.kerger@hubruxelles.be | 3 | 3 | ||
| 29375 | Saude Conde Rita | Multiple | Sotio | SN201 | Trial open for recruitment | A multicentric phase 1/2 trial to evaluate the safety and efficacy of SOT102 as monotherapy and in combination with standard of care treatment in patients with gastric and pancreatic adenocarcinoma (Sotio - SN201) | 1/2 | 1 | |||
| 22761 | Identified PIK3CA status | Ahmad Hussein Awada | Breast | Novartis | SOLAR-1 CBYL719C2301 | Trial closed | A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment CBYL719C2301 (SOLAR-1) | ahmad.awada@hubruxelles.be | 3 | 3 |